ArticleJCEM case reports2025
Late Diagnosis of X-Linked Arginine Vasopressin Resistance Presenting With Flow Uropathy in Adulthood.
Article in JCEM case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Congenital arginine vasopressin resistance (AVP-R) is a rare inherited disorder caused by renal unresponsiveness to arginine vasopressin (AVP), leading to persistent polyuria and polydipsia. We report a 19-year-old male individual with a long history of excessive thirst and urination who remained undiagnosed until adulthood. Despite normal growth and development, he was found to have bilateral hydronephrosis and underwent pyeloplasty at age 19. Postoperative fluid restriction resulted in life-threatening hypernatremia and seizures. Further evaluation revealed persistently low urine osmolality despite hypernatremia, elevated plasma copeptin, and no response to desmopressin or vasopressin, confirming AVP-R. Genetic testing identified a hemizygous arginine vasopressin receptor 2 (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.